KRAS G12C-mutant non-small-cell lung most cancers: biology, developmental therapeutics, and molecular testing KRAS mutation is the commonest oncogenic driver in superior non-small cell lung most cancers (NSCLC), occurring in roughly 30% of lung adenocarcinomas. Over 80% of oncogenic…